In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Reata Pharmaceuticals, Inc.

Latest From Reata Pharmaceuticals, Inc.

Biogen Asks For Yet More Patience As Leqembi Sales Begin Slow Ascent

CEO Chris Viehbacher outlined progress Biogen made in the third quarter, including full approval for the Eisai-partnered Alzheimer’s drug Leqembi, but recent wins will take time to make up for long-term revenue declines.

Growth Market Access

Finance Watch: Biopharma Firms Get Ahead Of Q3 Updates With Restructuring Reveals

Restructuring Edition: Biogen and Sana add to their layoff totals. Exscientia announced R&D program cuts while Syros, PTC, AM-Pharma, Societal CDMO, Nighthawk and Kinnate revealed layoffs to conserve cash. Also, Impel is exploring strategic options and Applied Molecular Transport will disappear in a merger with Cyclo.

Restructuring Finance Watch

Already Number One In Neuroscience, Roche Extends Ionis RNA Partnership To Tackle Alzheimer’s And Huntington’s

Roche’s long-serving head of partnering in neuroscience Tom Zioncheck talks about the company’s approach to collaboration and its newly-expanded partnership with Ionis in Huntington’s and Alzheimer’s disease.

Neurology Deals

Slow Q3 For Biopharma M&A Boosted By Biogen/Reata

Biogen’s acquisition of Reata lifted the third quarter’s M&A value above $13bn, but data from Evaluate show that acquisition activity cratered in both August and September.

Deals M & A
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals